Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L26 pseudogene 27 is classified as a human pseudogene, lacking confirmed protein-coding function or any known biological activity, molecular function, or therapeutic relevance. It shares sequence similarity with ribosomal protein L26 (RPL26) but does not encode a functional protein. There are no characterized roles in disease, no known drug interactions, nor any validated biomarker or safety profiles related to this gene[5][4]. This target is not considered a therapeutic target and is not a functional protein/receptor/enzyme. Its listing as a pseudogene means that it is not active in biological processes and should not be selected as a therapeutic or pharmacological target[5][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L26 pseudogene 27 (RPL26P27).